AbbVieRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AbbVieImmunology-led pharma built around Skyrizi and Rinvoq after the Humira patent cliff. Entered obesity in March 2025 by licensing Gubra's long-acting amylin analog GUB014295 (GUBamy) for $350M upfront and up to $1.875B in milestones, taking global development and commercialisation.
All metrics are vertically resized to show how they've changed over time. They're not on the same Y-axis. This chart is meant to compare trends, not values.
Values normalized to 0-100 scale for comparison. Hover for actual values.